Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma. An Investigator-Initiated, Prospective, Multicenter, Non-Interventional Trial.

NCT07870577 is registered in ClinicalTrials.gov with Comprehensive Cancer Center Munich (CCCM) as lead sponsor.

NCT NCT07870577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma. An Investigator-Initiated, Prospective, Multicenter, Non-Interventional Trial.
Lead sponsor
Comprehensive Cancer Center Munich (CCCM)
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2026
Completion date
December 31, 2028
Enrollment
79 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mibc, urothelial cancer